Insufficient financing
Management says additional capital is needed to fund future operations and laboratory growth.
- Scope
- Laboratory expansion and ongoing corporate overhead
- Materiality
- high
IMAC Holdings, Inc.
IMAC Holdings, Inc. is a U.S.-based specialty healthcare and life sciences company that now operates primarily through Ignite Proteomics, LLC. Ignite uses a patented RPPA proteomics platform to measure protein signaling and support oncology treatment decisions and biopharmaceutical drug development, while the legacy IMAC clinical operations remain part of the consolidated structure.
−7 611,5 %
−323,7 %
−12 554,9 %
0.09
0.09
| % | |
|---|---|
| Proteomics and oncology testing | 70% RPPA-based laboratory testing that quantifies protein signaling for cancer care and research. |
| Biopharmaceutical research services | 20% Analytical services used by drug developers for biomarker and translational research. |
| Clinical healthcare services | 10% Legacy outpatient and rehabilitation services billed to patients and third-party payers. |
The company sells primarily to oncology clinicians, hospitals, and biopharmaceutical companies that need...
- Oncology providersprimary
Clinicians and care centers that use Ignite's RPPA data to support cancer treatment decisions.
- Biopharmaceutical companiesprimary
Drug developers that buy protein-signaling analysis for translational research and development.
- Patients and payerssecondary
Patients and reimbursement sources tied to legacy outpatient and rehabilitation services.
IMAC Holdings is headquartered in the United States and its disclosed business activity is overwhelmingly U.S.-based...
- •United States is the core operating and revenue market
- •Laboratory growth depends on U.S. financing and staffing conditions
- •Clinical collections come from U.S. private and government payers
- •No meaningful country-level revenue disclosure was provided
- •Geography is operationally concentrated rather than globally diversified
Management is focused on funding the growth of its recently acquired laboratory and building out the Ignite Proteomics...
01
Secure financingshort-term
The company needs external capital to fund laboratory expansion and ongoing operations.
02
Commercialize Ignite Proteomicsmedium-term
Revenue is minimal, so adoption of the RPPA platform is essential to create scale.
03
Build operating capacityshort-term
Laboratory and sales staffing are needed to execute growth and manage overhead.
The company faces going-concern and liquidity risk because it continues to burn cash and depends on external financing...
Going-concern uncertainty
The company disclosed substantial doubt about its ability to continue as a going concern.
- Scope
- Entire business if funding is not secured
- Materiality
- high
Commercial adoption risk
Revenue is extremely small, so the RPPA platform must gain market acceptance to scale.
- Scope
- Ignite Proteomics revenue growth
- Materiality
- high
Specialized labor shortages
The company needs skilled laboratory and sales personnel at acceptable cost.
- Scope
- Operating capacity and overhead
- Materiality
- medium
Revenue recognition and collectability
Can affect reported revenue, receivables, and cash flow
Impairment of property and equipment
Can create sudden losses and reduce asset base
Going-concern disclosures
Affects investor assessment of liquidity and valuation
Discontinued operations
Can make trend analysis of core operations harder
: 28.4.2026